Budesonide Inhalation Powder: A Review of Its Pharmacologic Properties and Role in the Treatment of Asthma
Authors:
- Ralph E. SmallRSRalph E. Small
- 8 July 1998
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 18 (4) , 720-728
Abstract
Budesonide inhalation powder, available as Pulmicort Turbuhaler, is a corticosteroid with a high ratio of local to systemic effects that is administered to treat persistent asthma. The Turbuhaler achieves lung deposition approximately twice that of a metered‐dose inhaler (MDI) with or without a spacer device. Budesonide inhalation powder has clinical efficacy equivalent to that of fluticasone and beclomethasone, but it has lower systemic bioavailability and fewer systemic side effects. As with other inhaled corticosteroids, dysphonia and oral candidiasis are the most frequent adverse effects, and systemic effects are infrequent. The initial starting dosage is 200 μg (1 puff) twice/day and may be increased to 800 μg twice/day in adults or 400 μg twice/day in children. Patients prefer the Turbuhaler to the MDI, Diskhaler, and Rotahaler because it is easier to use and more convenient to carry.Keywords
This publication has 27 references indexed in Scilit:
- Comparison of the antiasthmatic, oropharyngeal, and systemic glucocorticoid effects of budesonide administered through a pressurized aerosol plus spacer or the Turbuhaler dry powder inhalerJournal of Allergy and Clinical Immunology, 1997
- Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patientsThorax, 1997
- Dose-Response of Inhaled Drugs in AsthmaClinical Pharmacokinetics, 1997
- Relative effects of inhaled corticosteroids on immunopathology and physiology in asthma: a controlled study.Thorax, 1996
- Changes in bone markers in children with asthma during inhaled budesonide and nedocromil treatmentsActa Paediatrica, 1996
- Long term clinical comparison of single versus twice daily administration of inhaled budesonide in moderate asthma.Thorax, 1995
- Clinical efficacy of budesonide Turbuhaler® compared with that of beclomethasone dipropionate pMDI with volumatic spacerAllergy, 1994
- Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDIEuropean Respiratory Journal, 1994
- Effects of dose and dosing schedule of inhaled budesonide on bone turnoverJournal of Allergy and Clinical Immunology, 1991
- Exercise-induced asthma and the generation of neutrophil chemotactic activityJournal of Allergy and Clinical Immunology, 1990